Granted Patent B2

US 12,352,695 · App. 18/122,180 · Granted Jul 8, 2025

Inventors: John L. Robertson (Floyd, VA); Ryan Senger (North Chesterfield, VA); Pang Du (Blacksburg, VA)

Assignee: Virginia Tech Intellectual Properties, Inc.

G01N21/65A61B5/0075A61B5/14525A61B5/6866A61M1/14A61M1/1609A61M1/1619A61M1/1692A61M1/282A61M1/3609G01N33/492G16H10/40G16H20/40A61M2205/3313A61M2205/50A61M2205/52G01N21/658G01N2570/00

Abstract

Claims (23)

1. A method comprising:

subjecting a patient to an initial dialysis treatment;

obtaining multiple urine and/or dialysate samples associated with the patient;

providing a Raman spectrum for each of the multiple samples associated with the patient;

detecting a molecular fingerprint of four or more analytes relative to one another in each of the Raman spectra and therefrom establishing analyte clearance kinetics indicative of progress of the dialysis treatment; and

treating the patient with one or more subsequent dialysis treatment(s) dependent on a disease state associated with the analyte clearance kinetics represented from the multiple samples of the patient;

wherein the subsequent dialysis treatment(s) is/are:

modified relative to the initial dialysis treatment; and

performed for a time, rate, and/or frequency based on the analyte clearance kinetics.

2. The method of claim 1 , wherein the samples are taken at the beginning, middle, and end of the initial dialysis treatment.

3. The method of claim 1 , wherein the multiple samples are dialysate samples.

4. The method of claim 1 , wherein the analytes are chosen from one or more of creatinine, uric acid, uric acid based compounds, interleukin-8, bilirubin, a1-anti-trypsin, arginine, homoarginine, urea, urea-based compounds, urea nitrogen based compounds, ammonium-based compounds, nitrogen-based compounds, vitamins, vitamin C, vitamin B12, folic acid, zinc, amino acids, proteins, nucleic acids, pharmaceutical compounds, 2-heptanal, 2-hexenal, 2-nonenal, 4-decenal, 4-HO-decenal, 4-HO-hexenal, 4-HO-nonenal, 4-HO-octenal, 4 pyrididone-3-carboxy-1-β-D-ribonucleoside, 8-Hydroxy-2′deoxyguanosine, α Keto δ guanidinovlaeric acid, antranilic acid, argininic acid, dimethylarginine, cysteine, decanal, dimethylamine, ethylamine, guanidine, guanidinoacetic acid, guanidine succinic acid, hepatanal, hexanal, hypoxanthine, malondialdehyde, methylguanidine, monomethylamine, neopterine, nicotinamide, N methyl-2-pyridone-5-carboxamide, N-methyl-4-pyridone-3-carboxamide, nonanal, noradrenaline, oxalate, phenylacetic acid, dimethylarginine, trimethylamine, trimethylamine-N-oxide, 3 carboxy-4-methyl-5-propyl-2-furan-propanoic acid, acrolein, carboxymethyllysine, dihydroxyphenylalanine, hippuric acid, homocysteine, indicant, indole-3-acetic acid, indoxyl sulfate, indoxyl-β-D-glucoronide, kynurenic acid, p-cresyl sulfate, pentosidine, phenol, putrescine, permidine, thiocyanate, α1-acid glycoprotein, α1-microglobulin, β-trace protein, β2 microglobulin, adiponectin, angiogenin, calcitonin, complement factor D, cystatin C, fibroblast growth factor-23, glutathione, reduced glutathione, insulin-like growth factor 1 (IGF-1), interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 10 (IL-10), leptin, myoglobin, osteocalcin, parathyroid hormone (PTH), prolactin, resistin, retinal binding protein, soluble intracellular adhesion molecule-1, tumor necrosis factor α (TNF-α), and vascular endothelial growth factor.

5. The method of claim 1 , wherein the treating involves hemodialysis.

6. The method of claim 1 , wherein the treating involves peritoneal dialysis.

7. The method of claim 1 , wherein one or more of the multiple samples is a waste dialysate.

8. The method of claim 1 , wherein the analytes comprise urea, urea-based compounds, urea nitrogen based compounds, sodium bicarbonate, glucose, fatty acids, triglycerides, and/or carbohydrates.

9. The method of claim 1 , wherein the analyte clearance kinetics are based on peaks of interest disposed at wavelengths of about 930 cm −1 , about 1000 cm −1 , about 1040 cm −1 , and/or about 1070 cm −1 .

10. The method of claim 1 , wherein the analyte clearance kinetics are based on changes over time of one or more of the four analytes relative to one another.

11. The method of claim 1 , wherein the samples are taken at different times.

12. The method of claim 1 , wherein the modifying of the subsequent dialysis treatment(s) comprises one or more of:

increasing or decreasing dialysis treatment time; and/or

increasing or decreasing the rate of blood flow through a dialyzer; and/or

increasing or decreasing the frequency of dialysis treatments.

Assignments (2)

Continuity (3)

References Cited (194)